Iqvia Holdings [IQV] vs Idexx Laboratories [IDXX] Detailed Stock Comparison
Iqvia Holdings
NYSE
Loading...
Idexx Laboratories
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Iqvia Holdings wins in 9 metrics, Idexx Laboratories wins in 10 metrics, with 0 ties. Idexx Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Iqvia Holdings | Idexx Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 27.69 | 54.06 | Iqvia Holdings |
| Price-to-Book Ratio | 5.62 | 35.76 | Iqvia Holdings |
| Debt-to-Equity Ratio | 272.12 | 84.81 | Idexx Laboratories |
| PEG Ratio | -1.25 | 1.11 | Iqvia Holdings |
| EV/EBITDA | 15.75 | 38.16 | Iqvia Holdings |
| Profit Margin (TTM) | 7.88% | 24.41% | Idexx Laboratories |
| Operating Margin (TTM) | 13.39% | 33.62% | Idexx Laboratories |
| EBITDA Margin (TTM) | 13.39% | 33.62% | Idexx Laboratories |
| Return on Equity | 19.79% | 64.87% | Idexx Laboratories |
| Return on Assets (TTM) | 5.16% | 23.26% | Idexx Laboratories |
| Free Cash Flow (TTM) | $2.11B | $798.08M | Iqvia Holdings |
| 1-Year Return | -20.26% | 32.21% | Idexx Laboratories |
| Price-to-Sales Ratio (TTM) | 2.07 | 12.90 | Iqvia Holdings |
| Enterprise Value | $46.05B | $53.14B | Idexx Laboratories |
| EV/Revenue Ratio | 2.93 | 13.16 | Iqvia Holdings |
| Gross Profit Margin (TTM) | 32.94% | 62.62% | Idexx Laboratories |
| Revenue per Share (TTM) | $89 | $50 | Iqvia Holdings |
| Earnings per Share (Diluted) | $6.90 | $12.04 | Idexx Laboratories |
| Beta (Stock Volatility) | 1.30 | 1.50 | Iqvia Holdings |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Iqvia Holdings vs Idexx Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Iqvia Holdings | 0.89% | 6.24% | 21.19% | 36.07% | -1.07% | -2.07% |
| Idexx Laboratories | -0.48% | -1.10% | 23.58% | 27.12% | 44.93% | 59.19% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Iqvia Holdings | -20.26% | -20.05% | 21.27% | 161.98% | 350.79% | 350.79% |
| Idexx Laboratories | 32.21% | 74.14% | 69.73% | 777.14% | 2,182.05% | 4,061.38% |
Performance & Financial Health Analysis: Iqvia Holdings vs Idexx Laboratories
| Metric | IQV | IDXX |
|---|---|---|
| Market Information | ||
| Market Cap | $32.49B | $52.07B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 1,321,850 | 983,296 |
| 90 Day Avg. Volume | 2,042,897 | 698,835 |
| Last Close | $191.09 | $650.84 |
| 52 Week Range | $134.65 - $252.88 | $356.14 - $688.12 |
| % from 52W High | -24.43% | -5.42% |
| All-Time High | $285.61 (Dec 27, 2021) | $706.95 (Jul 26, 2021) |
| % from All-Time High | -33.09% | -7.94% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.11% |
| Quarterly Earnings Growth | -0.27% | 0.45% |
| Financial Health | ||
| Profit Margin (TTM) | 0.08% | 0.24% |
| Operating Margin (TTM) | 0.13% | 0.34% |
| Return on Equity (TTM) | 0.20% | 0.65% |
| Debt to Equity (MRQ) | 272.12 | 84.81 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $33.99 | $18.20 |
| Cash per Share (MRQ) | $12.87 | $2.06 |
| Operating Cash Flow (TTM) | $2.62B | $905.81M |
| Levered Free Cash Flow (TTM) | $2.45B | $625.74M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Iqvia Holdings vs Idexx Laboratories
| Metric | IQV | IDXX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 27.69 | 54.06 |
| Forward P/E | 15.83 | 54.42 |
| PEG Ratio | -1.25 | 1.11 |
| Price to Sales (TTM) | 2.07 | 12.90 |
| Price to Book (MRQ) | 5.62 | 35.76 |
| Market Capitalization | ||
| Market Capitalization | $32.49B | $52.07B |
| Enterprise Value | $46.05B | $53.14B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.93 | 13.16 |
| Enterprise to EBITDA | 15.75 | 38.16 |
| Risk & Other Metrics | ||
| Beta | 1.30 | 1.50 |
| Book Value per Share (MRQ) | $33.99 | $18.20 |
Financial Statements Comparison: Iqvia Holdings vs Idexx Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IQV | IDXX |
|---|---|---|
| Revenue/Sales | $3.83B | $998.43M |
| Cost of Goods Sold | $2.53B | $375.05M |
| Gross Profit | $1.30B | $623.38M |
| Research & Development | N/A | $59.06M |
| Operating Income (EBIT) | $525.00M | $316.53M |
| EBITDA | $786.00M | $351.81M |
| Pre-Tax Income | $323.00M | $310.08M |
| Income Tax | $61.00M | $67.41M |
| Net Income (Profit) | $249.00M | $242.68M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IQV | IDXX |
|---|---|---|
| Cash & Equivalents | $1.74B | $163.97M |
| Total Current Assets | $5.91B | $1.32B |
| Total Current Liabilities | $7.18B | $1.14B |
| Long-Term Debt | $13.29B | $546.80M |
| Total Shareholders Equity | $5.99B | $1.45B |
| Retained Earnings | $6.31B | $5.58B |
| Property, Plant & Equipment | $768.00M | $833.62M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IQV | IDXX |
|---|---|---|
| Operating Cash Flow | $554.00M | $235.07M |
| Capital Expenditures | $-142.00M | $-30.03M |
| Free Cash Flow | $426.00M | $207.94M |
| Debt Repayment | $-2.10B | N/A |
| Common Stock Repurchase | $-375.00M | $-400.89M |
Short Interest & Institutional Ownership Analysis
| Metric | IQV | IDXX |
|---|---|---|
| Shares Short | 6.80M | 2.48M |
| Short Ratio | 2.96 | 4.68 |
| Short % of Float | 0.05% | 0.04% |
| Average Daily Volume (10 Day) | 1,321,850 | 983,296 |
| Average Daily Volume (90 Day) | 2,042,897 | 698,835 |
| Shares Outstanding | 176.10M | 81.60M |
| Float Shares | 161.43M | 79.13M |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.02% | 0.98% |
Dividend Analysis & Yield Comparison: Iqvia Holdings vs Idexx Laboratories
| Metric | IQV | IDXX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |